Trial Summary
What is the purpose of this trial?
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery.
Research Team
Craig G van Horne, MD, PhD
Principal Investigator
University of Kentucky
Eligibility Criteria
This trial is for people with Parkinson's Disease who are already planning to get deep brain stimulation (DBS) surgery. They should be diagnosed with idiopathic Parkinson's and willing to have additional experimental treatment involving their own nerve tissue implanted in the brain.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Reparative Autologous peripheral nerve tissue (Procedure)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Craig van Horne, MD, PhD
Lead Sponsor
National Institute on Aging (NIA)
Collaborator
Dr. Richard J. Hodes
National Institute on Aging (NIA)
Chief Executive Officer since 1993
MD from Harvard Medical School
Dr. Marie Bernard
National Institute on Aging (NIA)
Chief Medical Officer
MD from Harvard Medical School